BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31269743)

  • 1. A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.
    Gravel S; Panzini B; Belanger F; Turgeon J; Michaud V
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine.
    Clermont V; Grangeon A; Barama A; Turgeon J; Lallier M; Malaise J; Michaud V
    Br J Clin Pharmacol; 2019 Jun; 85(6):1367-1377. PubMed ID: 30817016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra-subject analysis.
    Fritz A; Busch D; Lapczuk J; Ostrowski M; Drozdzik M; Oswald S
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):245-255. PubMed ID: 30253071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
    Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis.
    Erdmann P; Bruckmueller H; Martin P; Busch D; Haenisch S; Müller J; Wiechowska-Kozlowska A; Partecke LI; Heidecke CD; Cascorbi I; Drozdzik M; Oswald S
    J Pharm Sci; 2019 Feb; 108(2):1035-1046. PubMed ID: 30267783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
    Hofman J; Sorf A; Vagiannis D; Sucha S; Kammerer S; Küpper JH; Chen S; Guo L; Ceckova M; Staud F
    Mol Pharm; 2019 Nov; 16(11):4436-4450. PubMed ID: 31633365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
    Chen C; Han YH; Yang Z; Rodrigues AD
    Xenobiotica; 2011 Jun; 41(6):476-85. PubMed ID: 21381897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of cytochromes P450, ABC transporters and their principal transcription factors in the amygdala and prefrontal cortex of alcoholics, smokers and drug-free controls by qRT-PCR.
    Toselli F; de Waziers I; Dutheil M; Vincent M; Wilce PA; Dodd PR; Beaune P; Loriot MA; Gillam EM
    Xenobiotica; 2015; 45(12):1129-37. PubMed ID: 26095139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the KRAS
    Loos NHC; Retmana IA; Rijmers J; Wang Y; Gan C; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2023 Oct; 166():115304. PubMed ID: 37586117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
    Gravel S; Chiasson JL; Turgeon J; Grangeon A; Michaud V
    Clin Pharmacol Ther; 2019 Dec; 106(6):1280-1289. PubMed ID: 31099895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal bacterial infections impact expression of drug transporters in human placenta.
    Petrovic V; Kojovic D; Cressman A; Piquette-Miller M
    Int Immunopharmacol; 2015 Jun; 26(2):349-56. PubMed ID: 25912346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
    Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
    Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.